Trials / Completed
CompletedNCT05151692
A Study of JNJ-80202135 in Healthy Chinese Adult Participants
A Sequential, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of JNJ-80202135 Following a Single Intravenous Administration in Healthy Chinese Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetic (PK) of nipocalimab following single intravenous (IV) administration in healthy Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nipocalimab | Nipocalimab will be administered as an IV infusion. |
Timeline
- Start date
- 2022-05-30
- Primary completion
- 2022-09-09
- Completion
- 2022-09-09
- First posted
- 2021-12-09
- Last updated
- 2022-10-26
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05151692. Inclusion in this directory is not an endorsement.